

TECHNICAL SPECIFICATIONS


| Drug / Excipient | |
|------------------|---|
| Drug | Sirolimus |
| Drug Dose | 1.4 µg/mm ² |
| Drug Carrier | Customized biodegradable polymer matrix |
| Stent | |
| Stent Material | L605 Cobalt Chromium Alloy |
| Stent Thickness | 73µm |
| Strut Width | 80µm(hinge) - 120µm (strut) |

| Delivery System | |
|-------------------------------|-------------|
| Delivery System | RX/Monorail |
| Nominal pressure | 8 Bar |
| Rated Burst Pressure | 14 Bar* |
| Guidewire compatibility (max) | 0.014" |
| Guide Catheter Compatibility | 5F |
| Crossing Profile** | 0.038" |
| Tip Entry Profile | 0.016" |

* Do not exceed RBP
 ** Reference diameter of 3.0mm

ORDERING INFORMATION

| Stent Dia (mm) | Stent Length (mm) | | | | | | | | | | | |
|----------------|-------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | 08 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 |
| 2.25 | EAN22508 | EAN22512 | EAN22516 | EAN22520 | EAN22524 | EAN22528 | EAN22532 | EAN22536 | EAN22540 | - | - | - |
| 2.50 | EAN25008 | EAN25012 | EAN25016 | EAN25020 | EAN25024 | EAN25028 | EAN25032 | EAN25036 | EAN25040 | EAN25044 | EAN25048 | EAN25052 |
| 2.75 | EAN27508 | EAN27512 | EAN27516 | EAN27520 | EAN27524 | EAN27528 | EAN27532 | EAN27536 | EAN27540 | - | - | - |
| 3.00 | EAN30008 | EAN30012 | EAN30016 | EAN30020 | EAN30024 | EAN30028 | EAN30032 | EAN30036 | EAN30040 | EAN30044 | EAN30048 | EAN30052 |
| 3.50 | EAN35008 | EAN35012 | EAN35016 | EAN35020 | EAN35024 | EAN35028 | EAN35032 | EAN35036 | EAN35040 | EAN35044 | EAN35048 | EAN35052 |
| 4.00 | EAN40008 | EAN40012 | EAN40016 | EAN40020 | EAN40024 | EAN40028 | EAN40032 | EAN40036 | EAN40040 | EAN40044 | EAN40048 | EAN40052 |
| 4.50 | EAN45008 | EAN45012 | EAN45016 | EAN45020 | - | - | - | - | - | - | - | - |
| 5.00 | EAN50008 | EAN50012 | EAN50016 | EAN50020 | - | - | - | - | - | - | - | - |




The above diagram is just an illustration of the product.
 The law restricts these devices to sale by or on the order of a physician, indications, contradictions, warnings a user instruction can be found in the product labelling//IFU supplied wit each device.
 For restricted use only in countries where product registered with applicable health authorities. All cited trademarks are the property of their respective owners.



ABLUMINUS DES+

SIROLIMUS ELUTING CORONARY STENT SYSTEM



DES + DCB* = DES+

Approved indication for DM & AMI



f t @ in /conceptmedicals

✉ info@conceptmedical.com

🌐 www.conceptmedical.com

Scan for more details




CB.ST.AN.BRO.ver.2.0.23-05


DIABETES MELLITUS

- Patients with DM are more affected by coronary artery disease and when treated by PCI with stent implantation they remain at higher risk of in-stent restenosis and adverse cardiovascular events.^[1-3]
- The etiology of this failure is likely to be multifactorial such as diffuse disease progression, small vessel and endothelial dysfunction.^[4-9]
- The presence of DM (particularly insulin-treated DM) has been a consistent, independent predictor of in-stent restenosis.^[10]




STENT COMPARISON*



* GG Stefanini, M Taniwaki, S Windecker, Coronary stents: novel development, Heart doi:10.1136/heartjnl-2012-303522; I Meredith, Scientific symposium, TCT 2013; M Rothman, presentation TCT 2014



CELL DESIGN



ABLUMINAL COATING

Facilitates mono directional drug release and less systemic exposure of drug leading to faster re-endothelialisation



FUSION COATING

Coating on the stent and exposed parts of the balloon facilitate homogeneous drug delivery which addresses diffused proliferative disease and focal restenosis



EDGE COATING

Additional 0.5mm coating beyond the proximal and distal edge of the balloon addresses the edge restenosis



BIODEGRADABLE FILM

The formation of hypothetical circular film with biodegradable polymer due to elasticity of polymer facilitate maximum surface area for drug delivery in blood wet conditions.



DES + DCB* = DES+

Designed to treat diabetic patients

*drug coating on exposed parts of balloon



References:

1. Kereiakes DJ et al. J Am Coll Cardiol 2010; 56: 2084-9. | 2. Cutlip DE et. al. Circulation 2004; 110: 1226-30. | 3. Lee TT et al. Am J Cardiol 2006; 98:718-21. | 4. Morgan KP et al. Heart 2004; 90: 732-8. | 5. Hadi H a R et al. Vasc Health Risk Manag 2007; 3:853-76. | 6. Schalkwijk CG et. Al Clin Sci 2005; 109: 143-59. | 7. Dangas GD et al. J. Am. Coll. Cardiol. 2010; 56:1897-907. | 8. Lightell DJ et al. Ochsner J 2013; 13:56-60. | 9. Denardo SJ et al. JAMA 2012; 307:2148-50. | 10. Popma, J.J. et al. Circulation 110, 3773-3780 (2004).